NAPP Logo

Biosimilars

Biosimilars

Biosimilar medicines:

We believe that biosimilar medicines represent a significant opportunity for the NHS and patients, and we are working with healthcare professionals and commissioners to help realise their potential and make a positive difference to patients.

Great Britain – Herzuma®▼ (trastuzumab) 150 mg powder for concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

 

SPC PIL

Northern Ireland – Herzuma®▼ (trastuzumab) 150 mg powder for concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

SPC PIL

Great Britain – Herzuma®▼ (trastuzumab) 420 mg powder for concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

SPC PIL

Northern Ireland – Herzuma®▼ (trastuzumab) 420 mg powder for concentrate for solution for infusion

 

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

SPC PIL

Truxima®▼ (rituximab) 100 mg concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

 

SPC PIL

Truxima®▼ (rituximab) 500 mg concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

 

SPC PIL

Pelmeg®▼ (pegfilgrastim) 6 mg solution for injection in pre-filled syringe 

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

 

SPC PIL
Back to all products

The following websites and documents offer information and resources for health professionals and/or patients:

Breast Cancer Now: A spotlight on biosimilars

Biosimilars for Lymphoma

Biosimilars in the EU: information guide for healthcare professionals

Commissioning framework for biological medicines (including biosimilar medicines)

Answers to commonly asked questions about biosimilar versions of rituximab

Biosimilars adoption

Guidelines on implementation of biosimilar monoclonal antibodies

Date of preparation: March 2021 UK-BIOS-2100001

Stay connected

You are now leaving our website. Napp does not accept any responsibility for the third party site.

Please click "Continue to external link" if you want to proceed.

Go Back
Continue to external link

Please confirm

We provide prescription only medicines for respiratory diseases, inflammatory conditions, pain management, cancer, diabetes and cardiovascular conditions. To access our product pages please click on the appropriate box below.

I am a
UK healthcare professional

I am a patient
or a member of the public
Date of preparation: March 2021 UK-BIOS-2100001

This area of the site is intended for UK health professionals only, including doctors, nurses, pharmacists, and anyone else who, in the course of their professional duties, may prescribe, apply or administer medicines. The information includes the summaries of product characteristics for our products and links to other websites that may be of interest.

I confirm I am a UK healthcare professional and would like to proceed to the product area of the Napp site I am a patient or a member of the public

This area of the site is intended for UK residents only. In this area of the site, you will find information about Napp’s medicines and links to other websites that may be of interest. This information is not intended as a substitute for the advice of a qualified health professional. If you have concerns about your health or the treatment you are receiving, we would encourage you to speak to your GP, pharmacist or another health professional.

I confirm that I have read the above and I wish to proceed to the product pages I do not wish to proceed to the product pages